Kairos Pharma (KAPA) Income from Continuing Operations (2023 - 2025)

Kairos Pharma (KAPA) has reported Income from Continuing Operations for 3 consecutive years, with -$1.4 million the latest figure, recorded in Q2 2025.

• For the quarter ending Q2 2025, Income from Continuing Operations fell 507.69% year-over-year to -$1.4 million; the trailing twelve-month figure through Jun 2025 stood at -$5.2 million (down 168.41% YoY), and the FY2025 full-year result was -$5.4 million, down 80.78% from the prior year.
• Income from Continuing Operations slipped to -$1.4 million in Q2 2025 per KAPA's latest filing, from -$1.3 million in the prior quarter.
• Across five years, Income from Continuing Operations topped out at -$234000.0 in Q2 2024 and bottomed at -$1.6 million in Q4 2024.
• Historically, Income from Continuing Operations has averaged -$889250.0 across 3 years, with a median of -$1.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations plunged 44.6% in 2024, then slumped 507.69% in 2025.
• Over 3 years, Income from Continuing Operations stood at -$1.1 million in 2023, then tumbled by 44.6% to -$1.6 million in 2024, then gained by 9.94% to -$1.4 million in 2025.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered -$1.4 million, -$1.3 million, and -$1.6 million for Q2 2025, Q1 2025, and Q4 2024 respectively.